At the clinical level, we report a correlation between the FGFR4-388Arg variant and higher N-cadherin expression in lung tumors, as well as an association of this FGFR4 variant with poorer outcomes for patients with NSCLC, regardless of histology. Here, FGFR4 is linked to non-small cell lung carcinoma.